Your browser doesn't support javascript.
loading
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
Gilson, Clare; Ingleby, Fiona; Gilbert, Duncan C; Parry, Marina A; Atako, Nafisah B; Ali, Adnan; Hoyle, Alex; Clarke, Noel W; Gannon, Melissa; Wanstall, Chris; Brawley, Christopher; Mason, Malcolm D; Malik, Zafar; Simmons, Andrew; Loehr, Andrea; Parry-Jones, Alison; Eeles, Rosalind; Kote-Jarai, Zsofia; James, Nicholas D; Amos, Claire; Parmar, Mahesh K B; Langley, Ruth E; Sydes, Matthew R; Attard, Gerhardt; Chowdhury, Simon.
Affiliation
  • Gilson C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Ingleby F; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Gilbert DC; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Parry MA; University College London Cancer Institute, London, United Kingdom.
  • Atako NB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Ali A; GU Research and FASTMAN groups, Manchester Cancer Institute, University of Manchester, Manchester, United Kingdom.
  • Hoyle A; GU Research and FASTMAN groups, Manchester Cancer Institute, University of Manchester, Manchester, United Kingdom.
  • Clarke NW; Department of Surgery, The Christie NHS Foundation Trust, Manchester and Salford Royal NHS Foundation Trusts, Manchester, United Kingdom.
  • Gannon M; GU Research and FASTMAN groups, Manchester Cancer Institute, University of Manchester, Manchester, United Kingdom.
  • Wanstall C; Department of Surgery, The Christie NHS Foundation Trust, Manchester and Salford Royal NHS Foundation Trusts, Manchester, United Kingdom.
  • Brawley C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Mason MD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Malik Z; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Simmons A; Cardiff University, Cardiff, United Kingdom.
  • Loehr A; Clatterbridge Cancer Centre, Liverpool, United Kingdom.
  • Parry-Jones A; Clovis Oncology, Boulder, CO.
  • Eeles R; Clovis Oncology, Boulder, CO.
  • Kote-Jarai Z; Cardiff University, Cardiff, United Kingdom.
  • James ND; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Amos C; Institute of Cancer Research, London, United Kingdom.
  • Parmar MKB; Institute of Cancer Research, London, United Kingdom.
  • Langley RE; Institute of Cancer Research, London, United Kingdom.
  • Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Attard G; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Chowdhury S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
JCO Precis Oncol ; 4: 882-897, 2020 Nov.
Article in En | MEDLINE | ID: mdl-35050761
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Type of study: Prevalence_studies / Risk_factors_studies Language: En Journal: JCO Precis Oncol Year: 2020 Type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Type of study: Prevalence_studies / Risk_factors_studies Language: En Journal: JCO Precis Oncol Year: 2020 Type: Article Affiliation country: United kingdom